findmyKOL

Mary Cambou, MD

Basic profile

University of California, Los Angeles

ORCIDNPI
RegionLos Angeles, CA · WestSpecialtyInfectious DiseaseFocusInfectious Disease
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNot yet checkedPaymentsNone reportedNIH funding2023–2026Why? →

Mary Cambou is an Infectious Disease physician affiliated with University of California, Los Angeles. OpenAlex indexes 64 publications with 808 citations (h-index 16).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
64publications

Distinct works indexed by OpenAlex, matched via ORCID.

808citations

Total citations across indexed works.

16h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1NIH grants · 2023–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1399 Roxbury Dr Ste 100
Los Angeles, CA 900354709

Telephone

310-557-2273

Provider last certified this registry record 25 Jul 2022.

View the NPPES registry record

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    26.9%
    Protease Inhibitor10.9%
    Prezcobix100%
    Part D<11 patients
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor8.3%
    Isentress100%
    Part D<11 patients

    + 1 more class in this area

  • Cardiovascular

    24.4%
    Calcium channel blocker8.3%
    Amlodipine Besylate100%
    Part D<11 patients
    Statin8.3%
    Atorvastatin Calcium100%
    Part D<11 patients

    + 1 more class in this area

  • Nervous system

    21.2%
    Aminoketone13.5%
    Bupropion Xl100%
    Part D<11 patients
    Nonergot Dopamine Agonist7.7%
    Pramipexole Dihydrochloride100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20232026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”